CDK4 and non-small cell lung carcinoma: In one phase 1 clinical trial with expansion cohorts in several different primary tumors, 68 molecularly unselected patients with previously-treated advanced NSCLC were treated with the CDK4/6 inhibitor, abemaciclib [21].